Our key goal is to demonstrate in vivo transformation of siRNA in the cell using our novel cyclic peptide platform. This will initially happen through:
Our partnership and collaboration with pharmaceutical companies that are facing challenges with the delivery of their compounds, including siRNA
Providing our proven technology platform to companies who have an interest in our platform.
Our mission is to use our extensive expertise in peptide chemistry to generate superior transfecting agents and therapeutic delivery solutions that substantially improve the delivery of oligonucleotides to genes in living cells.